Novidades

NOVEL APPLICATIONS AND INDICATIONS OF CELLULAR THERAPY

9.00 WELCOME BY Manuel Abecasis (APCL)

KEY NOTE LECTURE \\ CHAIRS: Arnon Nagler (Israel) and Ximo Duarte (IPO Lisbon)

09.10 \\ CD7-targeting CAR T cells and allogeneic CAR T cells: new players in the game? / Franco Locatelli (Itália)

09.50 Q&A

10.10 Coffee break 

CAR T cell therapy for large B-cell lymphoma

CHAIRS: João Lacerda (ULS Santa Maria) and Maria Gomes da Silva (IPO Lisbon)

10.40 \\ CAR T cells as second-line therapy for large B-cell lymphoma / José Mário Mariz (IPO Porto)

11.10 Q&A

11.20 \\ Short and long term toxicities of CAR T cell treatment as assessed by the EHA / EBMT grading for ICAHT: the Portuguese experience.

IPO Lisboa / Ana Carolina Freitas

IPO Porto / Claúdia Moreira 

ULS Santa Maria / Eduardo Espada

12.05 Q&A

12.20 – 13.20h Lunch

Multiple myeloma: CAR T cells vs. bispecifics in multiple myeloma

CHAIRS: Fernando Leal da Costa (IPO Lisbon) and Catarina Geraldes (ULS Coimbra)

13.20 \\ CAR T cells in myeloma / Maria Vitória Mateos (Espanha)

13.50 Q&A

14.05 \\ Bispecifics in multiple myeloma / Paulo Lúcio (Fundação Champalimaud)

14.35 Q&A

KEY NOTE LECTURE \\ CHAIRS: Manuel Abecasis (APCL) and Fernando Pimentel dos Santos (Sociedade Portuguesa de Reumatologia)

14.45 \\ CAR T cells: from hematology to autoimmunity / Arnon Nagler (Israel)

15.25 Q&A

15.40 Coffee break

Quality of life and patient access to cell therapies

CHAIR: José Mário Mariz (IPO Porto); Isabel Fernandes (DGS)

16.10 \\ Health related quality of life in patients treated with CAR T cells / Maria Gomes Silva (IPO Lisbon)

16.25 Q&A

16.35 \\ Does the Infarmed have a role in patient accessibility to CAR T cell therapy? / Claúdia Furtado (Infarmed)

16.50 Q&A

17.00 CLOSING OF THE CONFERENCE  Manuel Abecasis (APCL) and Tomás Lamas (Batazu)